• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.

作者信息

Armanini D, Karbowiak I, Goi A, Mantero F, Funder J W

出版信息

Clin Endocrinol (Oxf). 1985 Oct;23(4):341-7. doi: 10.1111/j.1365-2265.1985.tb01090.x.

DOI:10.1111/j.1365-2265.1985.tb01090.x
PMID:4064345
Abstract

We have established a sensitive and specific radioreceptor assay for androgen receptor active materials in plasma, using tritiated methyltrienolone ([3H]R1881) as tracer, and spayed mouse kidney cytosol receptor as the binding species. On radioreceptor assay, plasma from mice chronically administered spironolactone contained approximately 10 times higher levels of androgen receptor active material than from mice administered potassium canrenoate. In parallel bioassays (antagonism of the effect of testosterone on seminal vesicle weight), spironolactone was greater than 4 times as potent an antiandrogen as potassium canrenoate. Administered potassium canrenoate circulates as canrenoic acid, in equilibrium with its lactonized congener canrenone. Since over 80% of administered spironolactone is irreversibly converted to canrenone/canrenoic acid, its much higher anti-androgen activity on radioreceptor assay and bioassay may point to the generation of unidentified, minor metabolites with very high affinity for androgen receptors and/or a very long plasma half-life.

摘要

相似文献

1
In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.
Clin Endocrinol (Oxf). 1985 Oct;23(4):341-7. doi: 10.1111/j.1365-2265.1985.tb01090.x.
2
Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver.螺内酯和烯睾丙内酯对大鼠肝脏胞质及核雄激素和雌激素受体的影响。
Gastroenterology. 1987 Oct;93(4):681-6. doi: 10.1016/0016-5085(87)90428-8.
3
Spironolactone and potassium canrenoate in normal man.正常人中的螺内酯和坎利酸钾。
Clin Pharmacol Ther. 1976 Aug;20(2):167-77. doi: 10.1002/cpt1976202167.
4
Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.长期使用钾坎利酸钾或螺内酯治疗的肝硬化患者血浆中的坎利酮及雄激素受体活性物质
Digestion. 1989;44(3):155-62. doi: 10.1159/000199905.
5
Spironolactone and canrenoate-K: relative potency at steady state.螺内酯和坎利酸钾:稳态时的相对效价。
Clin Pharmacol Ther. 1977 May;21(5):602-9. doi: 10.1002/cpt1977215602.
6
Effects of repeated administration of potassium canrenoate (SC-14266) on serum gonadotrophin, prolactin, testosterone and progesterone in male rats.
Experientia. 1980 Jun 15;36(6):668-9. doi: 10.1007/BF01970128.
7
Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.螺内酯、坎利酮和坎利酸钾对牛和人肾上腺皮质线粒体中细胞色素P450以及11β-和18-羟化作用的影响。
Endocrinology. 1976 Oct;99(4):1097-106. doi: 10.1210/endo-99-4-1097.
8
Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.螺内酯、坎利酮及其共同代谢产物坎利酮对 Dimension Vista 地高辛检测的影响。
J Clin Lab Anal. 2010;24(6):413-7. doi: 10.1002/jcla.20421.
9
Increase in the basal tone of guinea pig thoracic aorta induced by ouabain is inhibited by spironolactone canrenone and potassium canrenoate.哇巴因诱导的豚鼠胸主动脉基础张力增加受到螺内酯、坎利酮和坎利酸钾的抑制。
J Cardiovasc Pharmacol. 1996 Oct;28(4):519-25. doi: 10.1097/00005344-199610000-00007.
10
Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings.螺内酯及其代谢产物对离体大鼠主动脉环收缩特性的影响。
J Cardiovasc Pharmacol. 2000 Aug;36(2):230-5. doi: 10.1097/00005344-200008000-00013.

引用本文的文献

1
Aldosterone in Gynecology and Its Involvement on the Risk of Hypertension in Pregnancy.醛固酮在妇科中的作用及其与妊娠高血压风险的关系。
Front Endocrinol (Lausanne). 2019 Aug 23;10:575. doi: 10.3389/fendo.2019.00575. eCollection 2019.
2
Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI.正常体重指数的多囊卵巢综合征患者中螺内酯与经间期出血
J Endocrinol Invest. 2016 Sep;39(9):1015-21. doi: 10.1007/s40618-016-0466-0. Epub 2016 Apr 12.
3
Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease.
醛固酮的治疗靶向:一种治疗肾小球疾病的新方法。
Clin Sci (Lond). 2015 May;128(9):527-35. doi: 10.1042/CS20140432.
4
Interfering with mineralocorticoid receptor activation: the past, present, and future.干扰盐皮质激素受体激活:过去、现在与未来。
F1000Prime Rep. 2014 Aug 1;6:61. doi: 10.12703/P6-61. eCollection 2014.
5
Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist.急性给予盐皮质激素受体拮抗剂导致皮质醇从人心脏移位。
J Clin Endocrinol Metab. 2014 Mar;99(3):915-22. doi: 10.1210/jc.2013-2049. Epub 2013 Jan 1.
6
Microalbuminuria and hypertension in pregnancy: role of aldosterone and inflammation.妊娠微量白蛋白尿与高血压:醛固酮和炎症的作用。
J Clin Hypertens (Greenwich). 2013 Sep;15(9):612-4. doi: 10.1111/jch.12135. Epub 2013 May 31.
7
Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate.特发性原发性醛固酮增多症:长期使用醛固酮受体拮抗剂坎利酸钾治疗停药1个月后血浆醛固酮恢复正常。
J Endocrinol Invest. 2005 Mar;28(3):236-40. doi: 10.1007/BF03345379.
8
Aldosterone receptor antagonists: biology and novel therapeutic applications.醛固酮受体拮抗剂:生物学特性与新型治疗应用
Curr Hypertens Rep. 2005 Jun;7(3):206-11. doi: 10.1007/s11906-005-0012-5.
9
Aldosterone receptor antagonists: biology and novel therapeutical applications.醛固酮受体拮抗剂:生物学特性与新型治疗应用
J Endocrinol Invest. 2003 Aug;26(8):788-98. doi: 10.1007/BF03347366.
10
Aldosterone receptor blockade in the management of heart failure.醛固酮受体阻滞剂在心力衰竭治疗中的应用
Heart Fail Rev. 2002 Apr;7(2):205-19. doi: 10.1023/a:1015336831407.